TriSalus Life Sciences, Inc. recently disclosed a significant stock transaction involving one of its directors, Gary B. Gordon. The transaction, which took place on November 17, 2026, involved the purchase of 10,000 shares of common stock at a price of $2.20 per share. This move is seen as a demonstration of confidence in the company's future prospects.

Background

TriSalus Life Sciences, Inc. operates in the surgical and medical instruments and apparatus sector, classified under SIC 3841. The company trades on the Nasdaq under the ticker symbols TLSI and TLSIW. Recent filings indicate that TriSalus is a smaller reporting company and has been active in the market, with several filings in the past month.

What the Filing Says

The filing, dated November 19, 2026, reveals that Gordon acquired 10,000 shares of TriSalus common stock. Following this transaction, he owns a total of 82,510 shares. The filing states, "Transaction Code: P" indicating a purchase of shares.

Impact

This stock purchase by a director may influence investor perception of TriSalus Life Sciences. It could signal to the market that insiders believe in the company's growth trajectory, particularly in the competitive landscape of surgical and medical instruments. The transaction may also affect shareholder sentiment and encourage other investors to consider the company's potential.

What's Next

The filing does not say what happens next.